ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
563.66M
Enterprise Value 3
309.23M
Trailing P/E
N/A
Forward P/E 1
-2.77
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
2.48
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-2.00

Trading Information

Stock Price History

Beta (3Y Monthly) 1.22
52-Week Change 3-36.05%
S&P500 52-Week Change 318.19%
52 Week High 316.76
52 Week Low 36.75
50-Day Moving Average 39.28
200-Day Moving Average 39.96

Share Statistics

Avg Vol (3 month) 3899.28k
Avg Vol (10 day) 3657.74k
Shares Outstanding 555.26M
Float 47.34M
% Held by Insiders 112.40%
% Held by Institutions 178.69%
Shares Short (Nov 15, 2019) 49.9M
Short Ratio (Nov 15, 2019) 416.17
Short % of Float (Nov 15, 2019) 425.82%
Short % of Shares Outstanding (Nov 15, 2019) 417.91%
Shares Short (prior month Oct 15, 2019) 49.43M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-29.06%
Return on Equity (ttm)-50.95%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-132.17M
EBITDA -154.44M
Net Income Avi to Common (ttm)-147.89M
Diluted EPS (ttm)-2.69
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)255.43M
Total Cash Per Share (mrq)4.62
Total Debt (mrq)22.56M
Total Debt/Equity (mrq)9.94
Current Ratio (mrq)7.77
Book Value Per Share (mrq)4.11

Cash Flow Statement

Operating Cash Flow (ttm)-122.09M
Levered Free Cash Flow (ttm)-73.1M